<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD full length article DTD version 4.2.37HW//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName arthw_4.2.37.dtd?><?SourceDTD.Version 4.2.37?><?ConverterInfo.XSLTName arthw2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="publisher-id">diacare</journal-id><journal-title>Diabetes Care</journal-title><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">3181608</article-id><article-id pub-id-type="doi">10.2337/dc08-0280</article-id><article-id pub-id-type="pmid">18443194</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pathophysiology/Complications</subject></subj-group></article-categories><title-group><article-title>Differences in the Contribution of the <italic>CTLA4</italic> Gene to Susceptibility to Fulminant and Type 1A Diabetes in Japanese Patients </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kawasaki</surname><given-names>Eiji</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Imagawa</surname><given-names>Akihisa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Makino</surname><given-names>Hideichi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uga</surname><given-names>Miho</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abiru</surname><given-names>Norio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hanafusa</surname><given-names>Toshiaki</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uchigata</surname><given-names>Yasuko</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Eguchi</surname><given-names>Katsumi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, Japan</aff><aff id="aff2"><label>2</label>First Department of Internal Medicine, Osaka Medical College, Osaka, Japan</aff><aff id="aff3"><label>3</label>Department of Laboratory Medicine, Ehime University School of Medicine, Ehime, Japan</aff><aff id="aff4"><label>4</label>Department of Endocrinology and Metabolism, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan</aff><aff id="aff5"><label>5</label>Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan</aff><author-notes><fn><p>Corresponding author: Eiji Kawasaki, <email>eijikawa&#x00040;nagasaki-u.ac.jp</email></p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><volume>31</volume><issue>8</issue><fpage>1608</fpage><lpage>1610</lpage><history><date date-type="received"><day>7</day><month>2</month><year>2008</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008, American Diabetes Association</copyright-statement><license license-type="open-access"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zdc00808001608.pdf"/><abstract><p><bold>OBJECTIVE</bold>&#x02014;To examine the contribution of the <italic>CTLA4</italic> gene in the susceptibility to fulminant type 1 diabetes and compare it with classic type 1A diabetes.</p><p><bold>RESEARCH DESIGN AND METHODS</bold>&#x02014;We genotyped the &#x0002b;49G&#x0003e;A and CT60G&#x0003e;A variants of the <italic>CTLA4</italic> gene in fulminant type 1 diabetic patients (<italic>n</italic> &#x0003d; 55), classic type 1A diabetic patients (<italic>n</italic> &#x0003d; 91), and healthy control subjects (<italic>n</italic> &#x0003d; 369). We also assessed serum levels of the soluble form of CTLA4 (sCTLA4).</p><p><bold>RESULTS</bold>&#x02014;The &#x0002b;49GG and CT60GG genotypes were associated with type 1A diabetes (<italic>P</italic> &#x0003c; 0.001). In contrast, the CT60AA genotype, but not the &#x0002b;49G&#x0003e;A variation, was associated with fulminant type 1 diabetes (<italic>P</italic> &#x0003c; 0.05), especially in patients carrying HLA-<italic>DR4</italic> (<italic>P</italic> &#x0003c; 0.01). Serum levels of sCTLA4 were significantly decreased in patients with fulminant type 1 diabetes (<italic>P</italic> &#x0003c; 0.05).</p><p><bold>CONCLUSIONS</bold>&#x02014;These results suggest that <italic>CTLA4</italic> CT60 affects the genetic susceptibility to fulminant type 1 diabetes. Furthermore, the contribution of <italic>CTLA4</italic> to disease susceptibility is distinct between fulminant type 1 diabetes and classic type 1A diabetes.</p></abstract></article-meta><notes><fn-group><fn><p>Published ahead of print at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org">http://care.diabetesjournals.org</ext-link> on 28 April 2008.</p><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p>Fulminant type 1 diabetes is a subtype of type 1 diabetes characterized by extremely rapid onset that can be classified as type 1B diabetes (<xref ref-type="bibr" rid="r1">1</xref>). Although frequent flu-like symptoms prior to onset suggest the contribution of virus infection in the etiology of fulminant type 1 diabetes, both environmental and genetic factors are largely unknown. Susceptibility to classic type 1A diabetes is determined by multiple genes within the HLA region and non-HLA genes, including <italic>INS-VNTR</italic>, <italic>CTLA4</italic>, and <italic>PTPN22</italic> (<xref ref-type="bibr" rid="r2">2</xref>). Among them, <italic>CTLA4</italic> is associated with autoimmunity, cancer, allergy, and infectious disease. In the <italic>CTLA4</italic> region, a number of variants, such as &#x0002b;49G&#x0003e;A and CT60, have shown type 1 diabetes association (<xref ref-type="bibr" rid="r3">3</xref>). Although the association between class II HLA and fulminant type 1 diabetes has been reported (<xref ref-type="bibr" rid="r4">4</xref>), the contribution of the non-HLA genes to the susceptibility to fulminant type 1 diabetes has not been investigated. In this study, we examined the genetic contribution of the <italic>CTLA4</italic> gene to fulminant type 1 diabetes compared with classic type 1A diabetes.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>We examined 55 patients with fulminant type 1 diabetes (49&#x00025; female, median age at onset 35.0 years), 91 patients with classic type 1A diabetes (57&#x00025; female, median age at onset 17.0 years), and 369 healthy control subjects. Diagnostic criteria for fulminant type 1 diabetes are described elsewhere (<xref ref-type="bibr" rid="r1">1</xref>). The criteria for the recruitment of type 1A diabetic patients were presence of diabetic ketosis at onset, duration of hyperglycemic symptoms &#x0003c;3 months prior to initiation of insulin therapy, and positive for at least one of the anti-islet autoantibodies. This study was approved by the appropriate ethics committees, and informed consent was obtained from all subjects.</p><p>Genotyping of two single nucleotide polymorphisms in the <italic>CTLA4</italic> gene, &#x0002b;49G&#x0003e;A (rs231775) and CT60 (rs3087243), was performed as reported previously (<xref ref-type="bibr" rid="r5">5</xref>). Serum concentration of sCTLA4 was measured by enzyme-linked immunosorbent assay using human soluble CTLA4 (sCTLA4) kit (MedSystems Diagnostics, Vienna, Austria), according to the manufacturer's protocol. Sera from type 1 diabetic patients were obtained at disease onset and stored at &#x02212;20&#x000b0;C until use.</p><p>The significance of differences in the distribution of genotypes between case and control subjects was determined by &#x003c7;<sup>2</sup> test or Fisher's exact probability test. Comparisons of the sCTLA4 levels were made by ANOVA with phenotypic group alone and ANOVA with phenotypic group and <italic>CTLA4</italic> genotype. <italic>P</italic> &#x0003c; 0.05 was considered to be statistically significant.</p></sec><sec><title>RESULTS</title><p>The &#x0002b;49G&#x0003e;A variant was associated with classic type 1A diabetes but not with fulminant type 1 diabetes (<xref ref-type="table" rid="t1">Table 1</xref>). In contrast, the contribution of CT60 to disease is distinct from that of &#x0002b;49G&#x0003e;A. The frequency of the CT60AA genotype in fulminant type 1 diabetic patients was significantly higher than in control subjects (<italic>P</italic> &#x0003d; 0.021) and type 1A diabetic patients (<italic>P</italic> &#x0003d; 0.031). CT60GG was associated with type 1A diabetes (<italic>P</italic> &#x0003d; 0.008). Because of the strong association of HLA-<italic>DR4</italic> in both patient groups (<xref ref-type="bibr" rid="r1">1</xref>), the effect of <italic>CTLA4</italic> on type 1 diabetes susceptibility relative to HLA-<italic>DR4</italic> was also examined. Among <italic>DR4</italic>-positive individuals, the frequency of the CT60AA genotype was significantly increased in patients with fulminant type 1 diabetes (<italic>P</italic> &#x0003d; 0.005). However, stratification of patients by the presence or absence of HLA-<italic>DR4</italic> did not affect the association between the &#x0002b;49GG genotype and type 1A diabetes (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>It has been reported that the CT60G allele might be associated with lower production of sCTLA4 mRNA (<xref ref-type="bibr" rid="r3">3</xref>). We therefore determined serum sCTLA4 levels. The mean sCTLA4 levels in fulminant type 1 diabetic patients (0.56 &#x000b1; 0.24 ng/ml &#x0005b;mean &#x000b1; SD&#x0005d;, <italic>n</italic> &#x0003d; 36) was significantly lower than those in type 1A diabetic patients (0.94 &#x000b1; 0.87 ng/ml, <italic>n</italic> &#x0003d; 45) and control subjects (0.89 &#x000b1; 0.76 ng/ml, <italic>n</italic> &#x0003d; 23) (<italic>P</italic> &#x0003d; 0.043). A mixed-model ANOVA using phenotypic group (fulminant type 1 diabetes, type 1A diabetes, and control) and CT60 genotype (GG and GA&#x0002b;AA) as factorial fixed effects revealed no differences in sCTLA4 levels between CT60 genotypes (<italic>P</italic> &#x0003d; 0.76) or phenotype/genotype interactions (<italic>P</italic> &#x0003d; 0.40).</p></sec><sec><title>CONCLUSIONS</title><p>CTLA4, which delivers inhibitory signals to T-cell activation, is expressed on the surface of activated T-cells and regulatory T-cells, and the lack of CTLA4 results in uncontrolled T-cell&#x02013;mediated lymphoproliferative disease (<xref ref-type="bibr" rid="r6">6</xref>). Furthermore, CTLA4 also has a significant biological role in attenuating T-cell responses in the context of an inflammatory environment, such as infection with a pathogen (<xref ref-type="bibr" rid="r7">7</xref>). We showed that <italic>CTLA4</italic> is associated with an increased risk of fulminant type 1 diabetes and that its contribution is distinct from classic type 1A diabetes. As reported previously (<xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r8">8</xref>), a significant association between classic type 1A diabetes and &#x0002b;49GG and CT60GG genotype was also found in the present study. However, the CT60AA genotype contributes to the susceptibility to fulminant type 1 diabetes. Moreover, it is implicated that HLA-<italic>DR4</italic> influences the association of fulminant type 1 diabetes with the CT60AA genotype.</p><p>In this study, we also revealed that serum sCTLA4 level in fulminant type 1 diabetic patients were significantly lower than those in type 1A diabetic patients and control subjects. Although it remains unknown how sCTLA4 regulates T-cell activation, recombinant sCTLA4 inhibits T-cell proliferation in vitro. Furthermore, sCTLA4 is constitutively expressed in nonstimulated T-cells, and its expression is downregulated after T-cell activation (<xref ref-type="bibr" rid="r9">9</xref>). Therefore, the decreased levels of sCTLA4 might indicate a lower potential of T-cell inhibition in fulminant type 1 diabetes, which might be caused by functional defects leading to reduced production of sCTLA4 or ongoing activation of the immune system eventually leading to decreased levels of sCTLA4.</p><p>In conclusion, the present study implicates that <italic>CTLA4</italic> confers susceptibility to fulminant type 1 diabetes. Furthermore, the different contributions of <italic>CTLA4</italic> to susceptibility to fulminant and classic type 1A diabetes indicate that the underlying immune process&#x02013;primed &#x003b2;-cell injury might be distinct between these subtypes of type 1 diabetes.</p></sec></body><back><ack><p>This study was partly supported by a grant from the Ministry of Education, Culture, Science, Sports and Technology of Japan.</p><p>We thank Shinobu Mitsui for excellent technical assistance.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal">Kawasaki E, Matsuura N, Eguchi K: Type 1 in Japan. <source>Diabetologia</source><volume>49</volume>:<fpage>828</fpage>&#x02013;836, <year>2006</year><pub-id pub-id-type="pmid">16568259</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal">Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <source>Nature</source><volume>447</volume>:<fpage>661</fpage>&#x02013;678, <year>2007</year><pub-id pub-id-type="pmid">17554300</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal">Vaidya B, Pearce S: The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. <source>Eur J Endocrinol</source><volume>150</volume>:<fpage>619</fpage>&#x02013;626, <year>2004</year><pub-id pub-id-type="pmid">15132716</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal">Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H: Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. <source>Diabetologia</source><volume>48</volume>:<fpage>294</fpage>&#x02013;300, <year>2005</year><pub-id pub-id-type="pmid">15688210</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal">Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mochizuki M, Ogihara T: The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. <source>J Clin Endocrinol Metab</source><volume>91</volume>:<fpage>1087</fpage>&#x02013;1092, <year>2006</year><pub-id pub-id-type="pmid">16352685</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal">Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. <source>Science</source><volume>270</volume>:<fpage>985</fpage>&#x02013;988, <year>1995</year><pub-id pub-id-type="pmid">7481803</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal">McCoy K, Camberis M, Gros GL: Protective immunity to nematode infection is induced by CTLA-4 blockade. <source>J Exp Med</source><volume>186</volume>:<fpage>183</fpage>&#x02013;187, <year>1997</year><pub-id pub-id-type="pmid">9221747</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal">Abe T, Yamaguchi Y, Takino H, Fujita N, Yamauchi DM, Ozaki M, Yamakawa K, Sera Y, Sakamaki H, Uotani S, Kawasaki E, Awata T, Yamasaki H, Eguchi K: CTLA4 gene polymorphism contributes to the mode of onset of diabetes with antiglutamic acid decarboxylase antibody in Japanese patients: genetic analysis of diabetic patients with antiglutamic acid decarboxylase antibody. <source>Diabet Med</source><volume>18</volume>:<fpage>726</fpage>&#x02013;731, <year>2001</year><pub-id pub-id-type="pmid">11606170</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal">Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ: A native soluble form of CTLA-4. <source>Cell Immunol</source><volume>201</volume>:<fpage>144</fpage>&#x02013;153, <year>2000</year><pub-id pub-id-type="pmid">10831323</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap position="float" id="t1"><label>Table 1</label><caption><p><italic>CTLA4</italic> polymorphisms in fulminant type 1 diabetic patients, type 1A diabetic patients, and healthy control subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom">Fulminant</th><th colspan="1" rowspan="1" align="center" valign="bottom">Type 1A</th><th colspan="1" rowspan="1" align="center" valign="bottom">Control</th><th colspan="3" rowspan="1" align="center" valign="bottom"><italic>P</italic> value <hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">OR (95&#x00025; CI) <hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom"/><th colspan="1" rowspan="1" align="center" valign="bottom">Fulminant vs. control</th><th colspan="1" rowspan="1" align="center" valign="bottom">Type 1A vs. control</th><th colspan="1" rowspan="1" align="center" valign="bottom">Fulminant vs. type 1A</th><th colspan="1" rowspan="1" align="center" valign="bottom">Fulminant vs. control</th><th colspan="1" rowspan="1" align="center" valign="bottom">Type 1A vs. control</th><th colspan="1" rowspan="1" align="center" valign="bottom">Fulminant vs. type 1A</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x0002b;49 G&#x0003e;A</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;<italic>n</italic></td><td colspan="1" rowspan="1" align="char" char="." valign="top">55</td><td colspan="1" rowspan="1" align="char" char="." valign="top">91</td><td colspan="1" rowspan="1" align="char" char="." valign="top">369</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AA</td><td colspan="1" rowspan="1" align="center" valign="top">13 (23.6)</td><td colspan="1" rowspan="1" align="center" valign="top">7 (7.7)</td><td colspan="1" rowspan="1" align="center" valign="top">61 (16.5)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AG</td><td colspan="1" rowspan="1" align="center" valign="top">23 (41.9)</td><td colspan="1" rowspan="1" align="center" valign="top">36 (39.6)</td><td colspan="1" rowspan="1" align="center" valign="top">186 (50.4)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;GG</td><td colspan="1" rowspan="1" align="center" valign="top">19 (34.5)</td><td colspan="1" rowspan="1" align="center" valign="top">48 (53.7)</td><td colspan="1" rowspan="1" align="center" valign="top">122 (33.1)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.0013</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.012</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;GG</td><td colspan="1" rowspan="1" align="center" valign="top">19 (34.5)</td><td colspan="1" rowspan="1" align="center" valign="top">48 (53.7)</td><td colspan="1" rowspan="1" align="center" valign="top">122 (33.1)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.0005</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.033</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">2.26 (1.41&#x02013;3.60)</td><td colspan="1" rowspan="1" align="center" valign="top">0.47 (0.24&#x02013;0.94)</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AA &#x0002b; AG</td><td colspan="1" rowspan="1" align="center" valign="top">36 (65.5)</td><td colspan="1" rowspan="1" align="center" valign="top">43 (46.3)</td><td colspan="1" rowspan="1" align="center" valign="top">247 (66.9)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">CT60 G&#x0003e;A</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;<italic>n</italic></td><td colspan="1" rowspan="1" align="char" char="." valign="top">55</td><td colspan="1" rowspan="1" align="char" char="." valign="top">91</td><td colspan="1" rowspan="1" align="char" char="." valign="top">369</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AA</td><td colspan="1" rowspan="1" align="center" valign="top">8 (14.5)</td><td colspan="1" rowspan="1" align="center" valign="top">4 (4.4)</td><td colspan="1" rowspan="1" align="center" valign="top">22 (6.0)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AG</td><td colspan="1" rowspan="1" align="center" valign="top">26 (47.3)</td><td colspan="1" rowspan="1" align="center" valign="top">28 (30.8)</td><td colspan="1" rowspan="1" align="center" valign="top">165 (44.7)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;GG</td><td colspan="1" rowspan="1" align="center" valign="top">21 (38.2)</td><td colspan="1" rowspan="1" align="center" valign="top">59 (64.8)</td><td colspan="1" rowspan="1" align="center" valign="top">182 (49.3)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.043</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.029</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.0036</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;GG</td><td colspan="1" rowspan="1" align="center" valign="top">21 (38.2)</td><td colspan="1" rowspan="1" align="center" valign="top">59 (64.8)</td><td colspan="1" rowspan="1" align="center" valign="top">182 (49.3)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.008</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.0017</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">1.89 (1.18&#x02013;3.05)</td><td colspan="1" rowspan="1" align="center" valign="top">0.33 (0.17&#x02013;0.67)</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AA &#x0002b; AG</td><td colspan="1" rowspan="1" align="center" valign="top">34 (61.8)</td><td colspan="1" rowspan="1" align="center" valign="top">32 (35.2)</td><td colspan="1" rowspan="1" align="center" valign="top">187 (50.7)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AA</td><td colspan="1" rowspan="1" align="center" valign="top">8 (14.5)</td><td colspan="1" rowspan="1" align="center" valign="top">4 (4.4)</td><td colspan="1" rowspan="1" align="center" valign="top">22 (6.0)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.021</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.031</td><td colspan="1" rowspan="1" align="center" valign="top">2.68 (1.13&#x02013;6.37)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">3.70 (1.06&#x02013;12.9)</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;AG &#x0002b; GG</td><td colspan="1" rowspan="1" align="center" valign="top">47 (85.5)</td><td colspan="1" rowspan="1" align="center" valign="top">87 (95.6)</td><td colspan="1" rowspan="1" align="center" valign="top">347 (94.0)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">DR4 (&#x0002b;)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;<italic>n</italic></td><td colspan="1" rowspan="1" align="char" char="." valign="top">42</td><td colspan="1" rowspan="1" align="char" char="." valign="top">52</td><td colspan="1" rowspan="1" align="char" char="." valign="top">121</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;&#x0002b;49GG</td><td colspan="1" rowspan="1" align="center" valign="top">14 (33.3)</td><td colspan="1" rowspan="1" align="center" valign="top">27 (51.9)</td><td colspan="1" rowspan="1" align="center" valign="top">38 (31.4)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.011</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">2.35 (1.21&#x02013;4.59)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;CT60AA</td><td colspan="1" rowspan="1" align="center" valign="top">8 (19.0)</td><td colspan="1" rowspan="1" align="center" valign="top">2 (3.8)</td><td colspan="1" rowspan="1" align="center" valign="top">6 (5.0)</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.005</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.018</td><td colspan="1" rowspan="1" align="center" valign="top">4.51 (1.46&#x02013;13.9)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">5.88 (1.18&#x02013;29.4)</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">DR4 (&#x02212;)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;<italic>n</italic></td><td colspan="1" rowspan="1" align="char" char="." valign="top">13</td><td colspan="1" rowspan="1" align="char" char="." valign="top">36</td><td colspan="1" rowspan="1" align="char" char="." valign="top">183</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;&#x0002b;49GG</td><td colspan="1" rowspan="1" align="center" valign="top">5 (38.5)</td><td colspan="1" rowspan="1" align="center" valign="top">19 (52.8)</td><td colspan="1" rowspan="1" align="center" valign="top">61 (33.3)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="char" char="." valign="top">0.026</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">2.24 (1.08&#x02013;4.61)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02003;&#x02003;&#x02003;CT60AA</td><td colspan="1" rowspan="1" align="center" valign="top">0 (0.0)</td><td colspan="1" rowspan="1" align="center" valign="top">3 (8.3)</td><td colspan="1" rowspan="1" align="center" valign="top">16 (8.7)</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="center" valign="top">NS</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>Data are <italic>n</italic> (&#x00025;). The interaction between <italic>CTLA4</italic> polymorphisms and HLA-<italic>DR4</italic> was assessed by a &#x003c7;<sup>2</sup> test with a 2 &#x000d7; 2 contingency table (&#x0002b;49 GG vs. AG &#x0002b; AA or CT60 AA vs. AG &#x0002b; GG) in <italic>DR4</italic>-positive or -negative patients and the corresponding control subjects.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 